Evidence map›Paper›PMID 40814801›Full record

ArticleHuman vaccines & immunotherapeutics2025

Distinct features of humoral and cellular immunity against Omicron breakthrough infection among chronic liver disease patients: An experience from a follow-up cohort.

Yongmei Liu, Yuzhu Shi, Haoting Zhan, Yuling Wang, Wenfang Yuan, Yuchen Xie, Linlin Cheng, Xinru Guo, Xiaomeng Li, Haiyan Kang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yongmei LiuDepartment of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Yuzhu ShiSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Haoting ZhanDepartment of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Yuling WangHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
Wenfang YuanHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
Yuchen XieSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Linlin ChengDepartment of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Xinru GuoSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Xiaomeng LiDepartment of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Haiyan KangHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
Haolong LiDepartment of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Yongliang ChenHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
Xingli SunHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
Huixia GaoHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
Fumin FengSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Erhei DaiHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
Yongzhe LiDepartment of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunity response following vaccination and infection toward the SARS-CoV-2 Omicron variant remains limited in chronic liver disease (CLD) population. This study aims to investigate humoral and cell-mediate immunity to Omicron BA.4/5 among CLD patients with/without breakthrough infections (BI). This longitudinal study characterized immune responses to Omicron infection across three CLD patient groups: vaccinated without BI (group 1, n = 10), vaccinated with BI (group 2, n = 43), and unvaccinated infected (group 3, n = 7). SARS-CoV-2-specific antibodies/T-cell responses and lymphocyte phenotypes were quantified by ELISA and flow cytometry. Logistic regression identified immunological correlates of BI event, viral clearance and liver disease progression. Dynamic immunity changes after infection analyzed using Spearman's correlation. Patients in group 2 exhibited the highest levels of neutralizing antibodies (NAbs) against wildtype (WT) and Omicron BA.4.5, anti-RBD IgG, and total anti-SARS-CoV-2 antibodies compared to groups 1 and 3. Comparable T cell responses were observed between two vaccinated groups, stronger than unvaccinated individuals. Hybrid immune (vaccination plus infection) elicited stronger NAbs-WT, total anti-SARS-CoV-2 antibodies, anti-RBD IgG, MBCs, and Omicron-specific IFN-γ

Indexed as

COVID-19COVID-19 VaccinesImmunity, CellularImmunity, HumoralLiver DiseasesSARS-CoV-2AdultAgedAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsChronic DiseaseFemaleFollow-Up StudiesHumansLongitudinal StudiesAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesdisease severityHybrid immunityimmunogenicityprognosisviral clearance

Identifiers

PMID40814801
PMCPMC12360197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.